

**Changes to legislation:** There are currently no known outstanding effects for the Regulation (EC) No 1907/2006 of the European Parliament and of the Council, ANNEX VIII. (See end of Document for details)

## [<sup>XI</sup>ANNEX VIII

### STANDARD INFORMATION REQUIREMENTS FOR SUBSTANCES MANUFACTURED OR IMPORTED IN QUANTITIES OF 10 TONNES OR MORE<sup>(1)</sup>

#### Editorial Information

- XI** Substituted by [Corrigendum to Regulation \(EC\) No 1907/2006 of the European Parliament and of the Council of 18 December 2006 concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals \(REACH\), establishing a European Chemicals Agency, amending Directive 1999/45/EC and repealing Council Regulation \(EEC\) No 793/93 and Commission Regulation \(EC\) No 1488/94 as well as Council Directive 76/769/EEC and Commission Directives 91/155/EEC, 93/67/EEC, 93/105/EC and 2000/21/EC \(Official Journal of the European Union L 396 of 30 December 2006\)](#).

Column 1 of this Annex establishes the standard information required for all substances manufactured or imported in quantities of 10 tonnes or more in accordance with Article 12(1) (c). Accordingly, the information required in column 1 of this Annex is additional to that required in column 1 of Annex VII. Any other relevant physicochemical, toxicological and ecotoxicological information that is available shall be provided. Column 2 of this Annex lists specific rules according to which the required standard information may be omitted, replaced by other information, provided at a different stage or adapted in another way. If the conditions are met under which column 2 of this Annex allows adaptations, the registrant shall clearly state this fact and the reasons for each adaptation under the appropriate headings in the registration dossier.

[<sup>F1</sup>Without prejudice to the information submitted for other forms, any relevant physicochemical, toxicological and ecotoxicological information shall include characterisation of the nanoform tested and test conditions. A justification shall be provided where QSARs are used or evidence is obtained by means other than testing, as well as a description of the range of the characteristics/properties of the nanoforms to which the evidence can be applied.]

#### Textual Amendments

- F1** Inserted by [Commission Regulation \(EU\) 2018/1881 of 3 December 2018 amending Regulation \(EC\) No 1907/2006 of the European Parliament and of the Council on the Registration, Evaluation, Authorisation and Restriction of Chemicals \(REACH\) as regards Annexes I, III, VI, VII, VIII, IX, X, XI, and XII to address nanoforms of substances \(Text with EEA relevance\)](#).

In addition to these specific rules, a registrant may adapt the required standard information set out in column 1 of this Annex according to the general rules contained in Annex XI. In this case as well, he shall clearly state the reasons for any decision to adapt the standard information under the appropriate headings in the registration dossier referring to the appropriate specific rule(s) in column 2 or in Annex XI<sup>(2)</sup>.

Before new tests are carried out to determine the properties listed in this Annex, all available *in vitro* data, *in vivo* data, historical human data, data from valid (Q)SARs and data from structurally related substances (read-across approach) shall be assessed first. *In vivo* testing with corrosive substances at concentration/dose levels causing corrosivity shall be avoided. Prior to testing, further guidance on testing strategies should be consulted in addition to this Annex.

When, for certain endpoints, information is not provided for other reasons than those mentioned in column 2 of this Annex or in Annex XI, this fact and the reasons shall also be clearly stated.

**Changes to legislation:** There are currently no known outstanding effects for the Regulation (EC) No 1907/2006 of the European Parliament and of the Council, ANNEX VIII. (See end of Document for details)

[<sup>F17</sup>. INFORMATION ON THE PHYSICOCHEMICAL PROPERTIES OF THE SUBSTANCE

7.14ter. Further information on physicochemical properties Only for nanoforms	Further testing for nanoforms covered by the registration shall be considered by the registrant or may be required by the Agency in accordance with Article 41, if there is an indication that specific additional particle properties significantly influence the hazard of or the exposure to those nanoforms.]
--	---

8. TOXICOLOGICAL INFORMATION

COLUMN 1 STANDARD INFORMATION REQUIRED	COLUMN 2 SPECIFIC RULES FOR ADAPTATION FROM COLUMN 1
[ <sup>F2</sup> 8.1. Skin corrosion/irritation	<p>8.1. An <i>in vivo</i> study for skin corrosion/irritation shall be considered only if the <i>in vitro</i> studies under points 8.1.1 and 8.1.2 in Annex VII are not applicable, or the results of these studies are not adequate for classification and risk assessment.</p> <p>The study does not need to be conducted if:</p> <ul style="list-style-type: none"> <li>— the substance is a strong acid (<math>\text{pH} \leq 2,0</math>) or base (<math>\text{pH} \geq 11,5</math>), or</li> <li>— the substance is spontaneously flammable in air or in contact with water or moisture at room temperature, or</li> <li>— the substance is classified as acute toxicity by the dermal route (Category 1), or</li> <li>— an acute toxicity study by the dermal route does not indicate skin irritation up to the limit dose level (2 000 mg/kg body weight).</li> </ul>
8.2. Serious eye damage/eye irritation	<p>8.2. An <i>in vivo</i> study for eye corrosion/irritation shall be considered only if the <i>in vitro</i> study(ies) under point 8.2.1 in Annex VII are not applicable, or the results obtained from these study(ies) are not adequate for classification and risk assessment.</p> <p>The study does not need to be conducted if:</p> <ul style="list-style-type: none"> <li>— the substance is classified as skin corrosion, or</li> <li>— the substance is a strong acid (<math>\text{pH} \leq 2,0</math>) or base (<math>\text{pH} \geq 11,5</math>), or</li> </ul>

**Changes to legislation:** There are currently no known outstanding effects for the Regulation (EC) No 1907/2006 of the European Parliament and of the Council, ANNEX VIII. (See end of Document for details)

	—	the substance is spontaneously flammable in air or in contact with water or moisture at room temperature.]
<b>8.4. Mutagenicity</b>		
8.4.2. <i>In vitro</i> cytogenicity study in mammalian cells or <i>in vitro</i> micronucleus study	8.4.2.	The study does not usually need to be conducted — if adequate data from an <i>in vivo</i> cytogenicity test are available, or — [F <sup>3</sup> the substance is known to be carcinogenic category 1A or 1B or germ cell mutagenic category 1A, 1B or 2.]
8.4.3. <i>In vitro</i> gene mutation study in mammalian cells, if a negative result in Annex VII, Section 8.4.1. and Annex VIII, Section 8.4.2.	8.4.3.	The study does not usually need to be conducted if adequate data from a reliable <i>in vivo</i> mammalian gene mutation test are available.
	8.4.	Appropriate <i>in vivo</i> mutagenicity studies shall be considered in case of a positive result in any of the genotoxicity studies in Annex VII or VIII.
[F <sup>2</sup> [F <sup>4</sup> 8.5. Acute toxicity	8.5.	The study/ies do(es) not generally need to be conducted if: — the substance is classified as corrosive to the skin. In addition to the oral route (8.5.1.) or to the inhalation route (8.5.2) for nanoforms, for substances other than gases, the information mentioned under 8.5.1. to 8.5.3. shall be provided for at least one other route. The choice for the second route will depend on the nature of the substance and the likely route of human exposure. If there is only one route of exposure, information for only that route needs to be provided.]
8.5.2. By inhalation	8.5.2.	Testing by the inhalation route is appropriate if exposure of humans via inhalation is likely taking into account the vapour pressure of the substance and/or the possibility of exposure to aerosols, particles or droplets of an inhalable size.
8.5.3. By dermal route	8.5.3.	Testing by the dermal route is appropriate if:

**Changes to legislation:** There are currently no known outstanding effects for the Regulation (EC) No 1907/2006 of the European Parliament and of the Council, ANNEX VIII. (See end of Document for details)

	<p>(1) inhalation of the substance is unlikely; and</p> <p>(2) skin contact in production and/or use is likely; and</p> <p>(3) the physicochemical and toxicological properties suggest potential for a significant rate of absorption through the skin.</p> <p>Testing by the dermal route does not need to be conducted if:</p> <ul style="list-style-type: none"> <li>— the substance does not meet the criteria for classification as acute toxicity or STOT SE by the oral route and</li> <li>— no systemic effects have been observed in <i>in vivo</i> studies with dermal exposure (e.g. skin irritation, skin sensitisation) or, in the absence of an <i>in vivo</i> study by the oral route, no systemic effects after dermal exposure are predicted on the basis of non-testing approaches (e.g. read across, QSAR studies).]</li> </ul>
<b>8.6.Repeated dose toxicity</b>	
<p>[<sup>F4</sup>8.6.1. Short-term repeated dose toxicity study (28 days), one species, male and female, most appropriate route of administration, having regard to the likely route of human exposure.</p>	<p>8.6.1. The short-term toxicity study (28 days) does not need to be conducted if:</p> <ul style="list-style-type: none"> <li>— a reliable sub-chronic (90 days) or chronic toxicity study is available, provided that an appropriate species, dosage, solvent and route of administration were used, or</li> <li>— where a substance undergoes immediate disintegration and there are sufficient data on the cleavage products, or</li> <li>— relevant human exposure can be excluded in accordance with Annex XI Section 3.</li> </ul> <p>The appropriate route shall be chosen on the following basis:</p> <p>Testing by the dermal route is appropriate if:</p> <ul style="list-style-type: none"> <li>— inhalation of the substance is unlikely, and</li> <li>— skin contact in production and/or use is likely, and</li> <li>— the physicochemical and toxicological properties suggest potential for a significant rate of absorption through the skin.</li> </ul>

---

**Changes to legislation:** There are currently no known outstanding effects for the Regulation (EC) No 1907/2006 of the European Parliament and of the Council, ANNEX VIII. (See end of Document for details)

---

Testing by the inhalation route is appropriate if exposure of humans via inhalation is likely taking into account the vapour pressure of the substance and/or the possibility of exposure to aerosols, particles or droplets of an inhalable size.

For nanoforms toxicokinetics shall be considered including recovery period and, where relevant, lung clearance.

The sub-chronic toxicity study (90 days) (Annex IX, Section 8.6.2) shall be proposed by the registrant if: the frequency and duration of human exposure indicates that a longer term study is appropriate;

and one of the following conditions is met:

- other available data indicate that the substance may have a dangerous property that cannot be detected in a short-term toxicity study, or
- appropriately designed toxicokinetic studies reveal accumulation of the substance or its metabolites in certain tissues or organs which would possibly remain undetected in a short-term toxicity study but which are liable to result in adverse effects after prolonged exposure.

Further studies shall be proposed by the registrant or may be required by the Agency in accordance with Article 40 or 41 in case of:

- failure to identify a NOAEL in the 28 or the 90 days study, unless the reason for the failure to identify a NOAEL is absence of adverse toxic effects, or
- toxicity of particular concern (e.g. serious/severe effects), or
- indications of an effect for which the available evidence is inadequate for toxicological and/or risk characterisation. In such cases it may also be more appropriate to perform specific toxicological studies that are designed to investigate these effects (e.g. immunotoxicity, neurotoxicity, and in particular for nanoforms indirect genotoxicity), or
- the route of exposure used in the initial repeated dose study was inappropriate in relation to the

**Changes to legislation:** There are currently no known outstanding effects for the Regulation (EC) No 1907/2006 of the European Parliament and of the Council, ANNEX VIII. (See end of Document for details)

	<p>expected route of human exposure and route-to-route extrapolation cannot be made, or</p> <p>— particular concern regarding exposure (e.g. use in consumer products leading to exposure levels which are close to the dose levels at which toxicity to humans may be expected), or</p> <p>— effects shown in substances with a clear relationship in molecular structure with the substance being studied, were not detected in the 28 or the 90 days study.]</p>
--	---

### 8.7.Reproductive toxicity

<p>8.7.1. Screening for reproductive/developmental toxicity, one species (OECD 421 or 422), if there is no evidence from available information on structurally related substances, from (Q)SAR estimates or from <i>in vitro</i> methods that the substance may be a developmental toxicant</p>	<p>[<sup>F5</sup>8.7.1. This study does not need to be conducted if:</p> <p>— the substance is known to be a genotoxic carcinogen and appropriate risk management measures are implemented, or</p> <p>— the substance is known to be a germ cell mutagen and appropriate risk management measures are implemented, or</p> <p>— relevant human exposure can be excluded in accordance with Annex XI section 3, or</p> <p>— a pre-natal developmental toxicity study (Annex IX, 8.7.2) or, either an Extended One-Generation Reproductive Toxicity Study (B.56, OECD TG 443) (Annex IX, section 8.7.3) or a two-generation study (B.35, OECD TG 416), is available.</p> <p>If a substance is known to have an adverse effect on fertility, meeting the criteria for classification as toxic for reproduction category 1A or 1B: May damage fertility (H360F), and the available data are adequate to support a robust risk assessment, then no further testing for fertility will be necessary. However, testing for developmental toxicity must be considered.</p> <p>If a substance is known to cause developmental toxicity, meeting the criteria for classification as toxic for reproduction category 1A or 1B: May damage the unborn child (H360D), and the available data are adequate to support a robust risk assessment,</p>
---	--

**Changes to legislation:** There are currently no known outstanding effects for the Regulation (EC) No 1907/2006 of the European Parliament and of the Council, ANNEX VIII. (See end of Document for details)

		then no further testing for developmental toxicity will be necessary. However, testing for effects on fertility must be considered. In cases where there are serious concerns about the potential for adverse effects on fertility or development, either an Extended One-Generation Reproductive Toxicity Study (Annex IX, section 8.7.3) or a pre-natal developmental toxicity study (Annex IX, section 8.7.2) may, as appropriate, be proposed by the registrant instead of the screening study.]
[ <sup>F4</sup> 8.8.	Toxicokinetics	
8.8.1.	Assessment of the toxicokinetic behaviour of the substance to the extent that can be derived from the relevant available information.	For nanoforms without high dissolution rate in biological media a toxicokinetics study shall be proposed by the registrant or may be required by the Agency in accordance with Article 40 or 41 in case such an assessment cannot be performed on the basis of relevant available information, including from the study conducted in accordance with 8.6.1. The choice of the study will depend on the remaining information gaps and the results of the chemical safety assessment.]

## 9. ECOTOXICOLOGICAL INFORMATION

<b>COLUMN 1 STANDARD INFORMATION REQUIRED</b>	<b>COLUMN 2 SPECIFIC RULES FOR ADAPTATION FROM COLUMN 1</b>
[ <sup>F4</sup> 9.1.3. Short-term toxicity testing on fish: the registrant may consider long-term toxicity testing instead of short-term.	<p>9.1.3. The study does not need to be conducted if:</p> <ul style="list-style-type: none"> <li>— there are mitigating factors indicating that aquatic toxicity is unlikely to occur, for instance the substance is highly insoluble in water or the substance is unlikely to cross biological membranes, or</li> <li>— a long-term aquatic toxicity study on fish is available.</li> </ul> <p>For nanoforms, the study may not be waived on the basis of high insolubility in water alone.</p> <p>Long-term aquatic toxicity testing as described in Annex IX shall be considered if the chemical safety assessment according to Annex I indicates the need to investigate further effects on aquatic organisms. The choice of the appropriate test(s) will</p>

**Changes to legislation:** There are currently no known outstanding effects for the Regulation (EC) No 1907/2006 of the European Parliament and of the Council, ANNEX VIII. (See end of Document for details)

	<p>depend on the results of the chemical safety assessment.</p> <p>The long-term aquatic toxicity study on fish (Annex IX, Section 9.1.6) shall be considered if the substance is poorly water soluble, or for nanoforms if they have low dissolution rate in the relevant test media.]</p>
<p>[<sup>F4</sup>9.1.4. Activated sludge respiration inhibition testing</p>	<p>9.1.4. The study does not need to be conducted if:</p> <ul style="list-style-type: none"> <li>— there is no emission to a sewage treatment plant, or</li> <li>— there are mitigating factors indicating that microbial toxicity is unlikely to occur, for instance the substance is highly insoluble in water, or</li> <li>— the substance is found to be readily biodegradable and the applied test concentrations are in the range of concentrations that can be expected in the influent of a sewage treatment plant.</li> </ul> <p>For nanoforms, the study may not be waived on the basis of high insolubility in water alone.</p> <p>The study may be replaced by a nitrification inhibition test if available data show that the substance is likely to be an inhibitor of microbial growth or function, in particular nitrifying bacteria.]</p>
<p>[<sup>F4</sup>9.2. Degradation</p>	<p>9.2. Further degradation testing shall be considered if the chemical safety assessment according to Annex I indicates the need to investigate further the degradation of the substance.</p> <p>For nanoforms that are not soluble, nor have high dissolution rate, such test(s) shall consider morphological transformation (e.g. irreversible changes in particle size, shape and surface properties, loss of coating), chemical transformation (e.g. oxidation, reduction) and other abiotic degradation (e.g. photolysis).</p> <p>The choice of the appropriate test(s) will depend on the results of the chemical safety assessment.]</p>
<p>[<sup>F4</sup>9.2.2. Abiotic</p>	<p>9.2.2.1. The study does not need to be conducted if:</p>



---

**Changes to legislation:** There are currently no known outstanding effects for the Regulation (EC) No 1907/2006 of the European Parliament and of the Council, ANNEX VIII. (See end of Document for details)

---

9.2.2.1. Hydrolysis as a function of pH.	<ul style="list-style-type: none"> <li>— the substance is readily biodegradable, or</li> <li>— the substance is highly insoluble in water.</li> </ul> <p>For nanoforms, the study may not be waived on the basis of high insolubility in water alone.]</p>
<b>9.3.Fate and behaviour in the environment</b>	
[ <sup>F4</sup> 9.3.1. Adsorption/desorption screening	<p>9.3.1. The study does not need to be conducted if:</p> <ul style="list-style-type: none"> <li>— based on the physicochemical properties the substance can be expected to have a low potential for adsorption (e.g. the substance has a low octanol-water partition coefficient), or</li> <li>— the substance and its relevant degradation products decompose rapidly.</li> </ul> <p>For nanoforms, use of any physicochemical property (e.g. octanol-water partition coefficient) as a reason for waiving the study shall include adequate justification of its relevance to low potential for adsorption.]]</p>

---

**Changes to legislation:** There are currently no known outstanding effects for the Regulation (EC) No 1907/2006 of the European Parliament and of the Council, ANNEX VIII. (See end of Document for details)

---

- (1) [<sup>X1</sup>This Annex shall apply to producers of articles that are required to register in accordance with Article 7 and to other downstream users that are required to carry out tests under this Regulation adapted as necessary.]
- (2) [<sup>X1</sup>Note: conditions for not requiring a specific test that are set out in [regulations under] Article 13(3) that are not repeated in column 2, also apply.]

---

**Editorial Information**

- X1** Substituted by [Corrigendum to Regulation \(EC\) No 1907/2006 of the European Parliament and of the Council of 18 December 2006 concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals \(REACH\), establishing a European Chemicals Agency, amending Directive 1999/45/EC and repealing Council Regulation \(EEC\) No 793/93 and Commission Regulation \(EC\) No 1488/94 as well as Council Directive 76/769/EEC and Commission Directives 91/155/EEC, 93/67/EEC, 93/105/EC and 2000/21/EC \(Official Journal of the European Union L 396 of 30 December 2006\).](#)

**Changes to legislation:**

There are currently no known outstanding effects for the Regulation (EC) No 1907/2006 of the European Parliament and of the Council, ANNEX VIII.